 | • レポートコード：QY2203B03171 • 出版社/出版日：QYResearch / 2022年3月25日 • レポート形態：英文、PDF、70ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界のジフテリア・破傷風・百日咳3種混合ワクチンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にジフテリア・破傷風・百日咳3種混合ワクチンの世界市場のxxx％を占める「子供」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「政府機関」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のジフテリア・破傷風・百日咳3種混合ワクチンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのジフテリア・破傷風・百日咳3種混合ワクチン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのジフテリア・破傷風・百日咳3種混合ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 ジフテリア・破傷風・百日咳3種混合ワクチンのグローバル主要メーカーには、Sanofi Pasteur、GSK、Wuhan Institutionなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ジフテリア・破傷風・百日咳3種混合ワクチン市場は、種類と用途によって区分されます。世界のジフテリア・破傷風・百日咳3種混合ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 子供、大人 【用途別セグメント】 政府機関、民間企業、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ジフテリア・破傷風・百日咳3種混合ワクチン製品概要 - 種類別市場（子供、大人） - 用途別市場（政府機関、民間企業、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のジフテリア・破傷風・百日咳3種混合ワクチン販売量予測2017-2028 - 世界のジフテリア・破傷風・百日咳3種混合ワクチン売上予測2017-2028 - ジフテリア・破傷風・百日咳3種混合ワクチンの地域別販売量 - ジフテリア・破傷風・百日咳3種混合ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ジフテリア・破傷風・百日咳3種混合ワクチン販売量 - 主要メーカー別ジフテリア・破傷風・百日咳3種混合ワクチン売上 - 主要メーカー別ジフテリア・破傷風・百日咳3種混合ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（子供、大人） - ジフテリア・破傷風・百日咳3種混合ワクチンの種類別販売量 - ジフテリア・破傷風・百日咳3種混合ワクチンの種類別売上 - ジフテリア・破傷風・百日咳3種混合ワクチンの種類別価格 ・用途別市場規模（政府機関、民間企業、その他） - ジフテリア・破傷風・百日咳3種混合ワクチンの用途別販売量 - ジフテリア・破傷風・百日咳3種混合ワクチンの用途別売上 - ジフテリア・破傷風・百日咳3種混合ワクチンの用途別価格 ・北米市場 - 北米のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのジフテリア・破傷風・百日咳3種混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのジフテリア・破傷風・百日咳3種混合ワクチン市場規模（種類別、用途別） - 主要国別のジフテリア・破傷風・百日咳3種混合ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Sanofi Pasteur、GSK、Wuhan Institution ・産業チェーン及び販売チャネル分析 - ジフテリア・破傷風・百日咳3種混合ワクチンの産業チェーン分析 - ジフテリア・破傷風・百日咳3種混合ワクチンの原材料 - ジフテリア・破傷風・百日咳3種混合ワクチンの生産プロセス - ジフテリア・破傷風・百日咳3種混合ワクチンの販売及びマーケティング - ジフテリア・破傷風・百日咳3種混合ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ジフテリア・破傷風・百日咳3種混合ワクチンの産業動向 - ジフテリア・破傷風・百日咳3種混合ワクチンのマーケットドライバー - ジフテリア・破傷風・百日咳3種混合ワクチンの課題 - ジフテリア・破傷風・百日咳3種混合ワクチンの阻害要因 ・主な調査結果 |
DTaP (diphtheria, tetanus, and acellular pertussis) vaccine, which is given to children. DT (diphtheria and tetanus) vaccine, which is given to children. Tdap (combined tetanus, diphtheria and acellular pertussis) vaccine, which is given to adolescents and adults.
Market Analysis and Insights: Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market
Due to the COVID-19 pandemic, the global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Child accounting for % of the Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Government Institution segment is altered to an % CAGR throughout this forecast period.
China Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market size is valued at US$ million in 2021, while the US and Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine include Sanofi Pasteur, GSK and Wuhan Institution, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Scope and Segment
Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Child
Adult
Segment by Application
Government Institution
Private Sector
Other
By Company
Sanofi Pasteur
GSK
Wuhan Institution
By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Child
1.2.3 Adult
1.3 Market by Application
1.3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region
2.4.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by Region (2023-2028)
2.5 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region
2.5.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2017-2022)
2.5.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Manufacturers
3.1.1 Global Top Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine in 2021
3.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Manufacturers
3.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue in 2021
3.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type
4.1.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type
4.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type
4.3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type (2017-2022)
4.3.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application
5.1.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application
5.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application
5.3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application (2017-2022)
5.3.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Type
6.1.1 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2028)
6.1.2 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2028)
6.2 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Application
6.2.1 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2028)
6.2.2 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2028)
6.3 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country
6.3.1 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2028)
6.3.2 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2028)
6.3.3 the United States
6.3.4 Canada
7 Europe
7.1 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Type
7.1.1 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2028)
7.1.2 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2028)
7.2 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Application
7.2.1 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2028)
7.2.2 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2028)
7.3 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country
7.3.1 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2028)
7.3.2 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 UK
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Type
8.1.1 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Application
8.2.1 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Region
8.3.1 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Type
9.1.1 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2028)
9.2 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Application
9.2.1 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2028)
9.3 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country
9.3.1 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Type
10.1.1 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Application
10.2.1 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country
10.3.1 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Corporation Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Pasteur Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Wuhan Institution
11.3.1 Wuhan Institution Corporation Information
11.3.2 Wuhan Institution Overview
11.3.3 Wuhan Institution Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Wuhan Institution Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Wuhan Institution Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Chain Analysis
12.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Production Mode & Process
12.4 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales and Marketing
12.4.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Channels
12.4.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Distributors
12.5 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Trends
13.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Drivers
13.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Challenges
13.4 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Restraints
14 Key Findings in The Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Child
Table 3. Major Manufacturers of Adult
Table 4. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2017-2022) & (K Units)
Table 7. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2023-2028) & (K Units)
Table 9. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Manufacturers (2017-2022) &(USD/Unit)
Table 19. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine as of 2021)
Table 21. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 26. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 27. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Type (2017-2022)
Table 28. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Type (2023-2028)
Table 29. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Type (2023-2028)
Table 33. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type (2017-2022) & (USD/Unit)
Table 34. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price Forecast by Type (2023-2028) & (USD/Unit)
Table 35. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 36. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 37. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Application (2017-2022)
Table 38. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Application (2023-2028)
Table 39. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Application (2023-2028)
Table 43. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application (2017-2022) & (USD/Unit)
Table 44. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price Forecast by Application (2023-2028) & (USD/Unit)
Table 45. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 46. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 47. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 50. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 51. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 54. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 55. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 58. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 59. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 62. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 63. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 66. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 67. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Sanofi Pasteur Corporation Information
Table 106. Sanofi Pasteur Description and Major Businesses
Table 107. Sanofi Pasteur Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 108. Sanofi Pasteur Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Sanofi Pasteur Recent Developments
Table 110. GSK Corporation Information
Table 111. GSK Description and Major Businesses
Table 112. GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 113. GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GSK Recent Developments
Table 115. Wuhan Institution Corporation Information
Table 116. Wuhan Institution Description and Major Businesses
Table 117. Wuhan Institution Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 118. Wuhan Institution Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Wuhan Institution Recent Developments
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Distributors List
Table 123. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Customers List
Table 124. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Trends
Table 125. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Drivers
Table 126. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Challenges
Table 127. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Picture
Figure 3. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Share by Type in 2021 & 2028
Figure 3. Child Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Share by Application in 2021 & 2028
Figure 6. Government Institution
Figure 7. Private Sector
Figure 8. Other
Figure 9. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Report Years Considered
Figure 10. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales 2017-2028 (K Units)
Figure 11. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue 2017-2028 (US$ Million)
Figure 13. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2017-2022)
Figure 15. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2023-2028)
Figure 16. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales YoY (2017-2028) & (K Units)
Figure 17. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales YoY (2017-2028) & (K Units)
Figure 19. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales YoY (2017-2028) & (K Units)
Figure 21. Asia-Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales YoY (2017-2028) & (K Units)
Figure 23. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales YoY (2017-2028) & (K Units)
Figure 25. Middle East & Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine in the World: Market Share by Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue in 2021
Figure 28. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 32. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 33. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 34. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 35. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 36. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 37. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 38. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 39. the United States Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 42. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 43. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 45. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 46. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 47. Germany Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 48. France Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. UK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 53. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 54. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Region (2017-2028)
Figure 58. China Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. China Taiwan Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 70. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 72. Latin America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 73. Mexico Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Country (2017-2028)
Figure 82. Turkey Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Value Chain
Figure 86. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed